Traders Buy High Volume of Call Options on Cybin (NASDAQ:HELP)

Cybin Inc. (NASDAQ:HELP – Get Free Report) saw unusually large options trading on Monday. Investors acquired 3,723 call options on the stock. This is an increase of approximately 108% compared to the average daily volume of 1,786 call options.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. TD Cowen upped their price target on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Wall Street Zen cut shares of Cybin from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Wells Fargo & Company increased their target price on Cybin from $16.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, October 22nd. Finally, Barclays started coverage on Cybin in a research report on Friday, September 18th. They set an “overweight” rating and a $35.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Cybin has a consensus rating of “Buy” and an average target price of $47.33.

View Our Latest Analysis on Cybin

Cybin Stock Down 11.2%

NASDAQ:HELP traded down $0.99 during trading hours on Monday, hitting $7.88. 10,994,020 shares of the company’s stock traded hands, compared to its average volume of 1,327,331. The business’s fifty day simple moving average is $11.24 and its two-hundred day simple moving average is $7.81. Cybin has a 52 week low of $3.76 and a 52 week high of $15.15. The firm has a market cap of $628.82 million, a P/E ratio of -2.64 and a beta of 0.64.

Cybin (NASDAQ:HELP – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.74). On average, analysts expect that Cybin will post -2.95 EPS for the current year.

Insider Transactions at Cybin

In other Cybin news, insider Paul Glavine acquired 100,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were acquired at an average cost of $12.47 per share, with a total value of $1,247,000.00. Following the completion of the acquisition, the insider directly owned 4,271,252 shares in the company, valued at $53,262,512.44. This trade represents a 2.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric H. L. So bought 100,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were acquired at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the transaction, the insider directly owned 4,465,014 shares of the company’s stock, valued at approximately $55,321,523.46. This trade represents a 2.29% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 688,000 shares of company stock worth $8,422,830. Insiders own 15.00% of the company’s stock.

Institutional Trading of Cybin

A number of hedge funds have recently made changes to their positions in the stock. WealthPlan Investment Management LLC bought a new position in shares of Cybin during the 3rd quarter valued at about $1,272,000. Pale Fire Capital SE bought a new stake in Cybin in the 2nd quarter worth approximately $1,015,000. Farther Finance Advisors LLC boosted its stake in Cybin by 927.4% in the third quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company’s stock worth $280,000 after buying an additional 20,597 shares in the last quarter. AXQ Capital LP purchased a new stake in Cybin in the second quarter worth approximately $75,000. Finally, Blue Owl Capital Holdings LP grew its position in Cybin by 381.2% during the third quarter. Blue Owl Capital Holdings LP now owns 288,282 shares of the company’s stock valued at $3,543,000 after acquiring an additional 228,371 shares during the last quarter. 17.94% of the stock is owned by institutional investors.

Cybin Company Profile

(Get Free Report)

Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.

Read More

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.